**PEDIATRIC BRAIN**

*ACNS 0332*: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients.


*ACNS 02B3*: Children's Oncology Group (COG) Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens.

[https://clinicaltrials.gov/ct2/show/NCT00919750?term=02b3&rank=1](https://clinicaltrials.gov/ct2/show/NCT00919750?term=02b3&rank=1)

*ACNS 0831*: Randomized Trial of Post-Radiation Chemotherapy in Patients with newly Diagnosed Ependymoma Ages 1-21 Years: A Group wide Phase III Study.


*ACNS 1123*: Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS-GCT).


**COMPANION STUDIES**

*ACCRN 07*: Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN).


*POG 9902*: COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol.

For General Referrals, please call: 407-303-2090

ABTR 01B1: COG Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors.

https://clinicaltrials.gov/ct2/show/NCT00898079?term=abtr+01b1&rank=2

ALTE 07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer.

https://clinicaltrials.gov/ct2/show/NCT00772200?term=ALTE+07C1&rank=1

ALTE 1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

https://clinicaltrials.gov/ct2/show/NCT02717507?term=ALTE+1621&rank=1

CANCER CONTROL

ALTE 05N1: Umbrella Long-Term Follow-Up Protocol.

https://clinicaltrials.gov/ct2/show/NCT00736749?term=ALTE+05N1&rank=1

NEUROBLASTOMA & OTHER EMBRYONAL TUMORS

ANBL 00B1: Neuroblastoma Biology Studies.

https://clinicaltrials.gov/ct2/show/NCT011117168?term=COG+registry&rank=1

ANBL1221: Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma.

https://clinicaltrials.gov/ct2/show/NCT01767194?term=ANBL1221&rank=1

ANBL1232: Utilizing Response and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma.

https://clinicaltrials.gov/ct2/show/NCT02176967?term=ANBL1232&rank=1
LYMPHOMAS/HODGKIN’S DISEASE

AHOD1331: Randomized Study of Brentuximab Vedotin (SGN-35, IND # 117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents.

https://clinicaltrials.gov/ct2/show/NCT02166463?term=AHOD1331&rank=1

ANHL12P1: Randomized Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC# 749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL).

https://clinicaltrials.gov/ct2/show/NCT01979536?term=ANHL12P1&rank=1

NATIONAL WILM’S TUMOR STUDY

POG 9442: National Wilms Tumor Late Effects Study.

https://clinicaltrials.gov/ct2/show/NCT00736749?term=ALTE05N1&rank=1

AREN03B2: Renal tumors Classification, Biology, and Banking Study.

https://clinicaltrials.gov/ct2/show/NCT00898365?term=AREN03B2&rank=1

HEPATOBLASTOMA TUMORS

AHEP 0731: Treatment of Children with All Stages of Hepatoblastoma.

https://clinicaltrials.gov/ct2/show/NCT00980460?term=AHEP+0731&rank=1

MULTI DISEASE SITES

ADVL 1522: Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma.

https://clinicaltrials.gov/ct2/show/NCT02452554?term=advl+1522&rank=1
**APEC 14B1:** The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study.


---

**BONE & SOFT TISSUE SARCOMAS**

**AOST 06B1:** A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens.


**AEWS 07B1:** A Children's Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens.


**AEWS 1031:** Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma.


**AEWS 1221:** Randomized Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND # 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma.


**AOST 1321:** Phase 2 Study of Denosumab (IND#127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma


**ARST 1321:** Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS), a Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

LEUKEMIA (ALL)

**AALL 05B1:** COG Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens.

https://clinicaltrials.gov/ct2/show/NCT00897325?term=AALL+05B1&rank=1

**AALL 08B1:** Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL).


**AALL 0932:** Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy).

https://clinicaltrials.gov/ct2/show/NCT01190930?term=AALL+0932&rank=1

**AALL 1131:** Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (B-ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum – Including a stratum evaluating Dasatinib (IND# 73789, NSC# 732517) in patients w/ Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

https://clinicaltrials.gov/ct2/show/NCT02883049?term=AALL+1131&rank=1

**AALL 1231:** Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy).

https://clinicaltrials.gov/ct2/show/NCT02112916?term=AALL+1231&rank=1

**AALL 1331:** Risk-Stratified Randomized Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

https://clinicaltrials.gov/ct2/show/NCT02101853?term=AALL+1331&rank=1

LEUKEMIA (AML)

**AAML 08B1:** Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS).

https://clinicaltrials.gov/ct2/results?term=AAML+08B1&Search=Search
**AAML 1031:** Randomized Trial for Patients with de novo AML Using Bortezomib and Sorafenib (IND# 114480; NSC# 681239; NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.


**AAML 1331:** A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid


**AAML 1531:** Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome (DS).